Atrium Therapeutics, Inc. (RNA) Stock: Price, Forecast & Analyst Target
Atrium Therapeutics, Inc. (RNA) — MoonshotScore 35/100 (Weak band), calculated Nov 18, 2026. Price $6.64 (+2.47%), as of the Nov 18, 2026 trading session; market cap $143M.
Educational signal · not a buy or sell recommendation · How to read this
Atrium Therapeutics, Inc. · RNA · NASDAQ
Atrium Therapeutics, Inc. is a biopharmaceutical company focused on developing RNA therapeutics for cardiomyopathies. Their pipeline includes siRNA-based therapies targeting genetic and cardiac diseases, aiming to transform heart disease treatment.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Atrium Therapeutics (RNA)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
A fortress balance sheet, but bottom-tier quality, weak growth and a full valuation, and the price trend has turned against it. The score also carries a risk penalty for being loss-making and burning cash. Business Quality: Poor; Financial Safety: Fortress; Valuation: Full; Growth Durability: Fading; Momentum: Slipping.
- EPS beat 0 of the last 3 reports
- ROE -95.0% · ROA -34.8% · current ratio 10.46
Holding back: weak fundamentals, weak price trend
Helping: balance-sheet strength
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 35 | Weak | |
| 35 | Weak | |
| 38 | Weak | |
| 38 | Weak | |
| 35 | Weak | |
| 35 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $6.64 | |
| Change on the day | +2.47% | |
| 52-week range | $6.64 – $16.77 | |
| Market capitalisation | $143M | — |
| Shares traded on the day | 220.8K |
Price & events
Other perspectives
Council score for Atrium Therapeutics (RNA): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company more favourably than the MoonshotScore does: Griffin-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 18, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Atrium Therapeutics (RNA), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Atrium Therapeutics, Inc. (RNA) is listed on NASDAQ. It employs 511 people and is led by Kathleen Gallagher. The market values it at $143M.
What do the latest results show for Atrium Therapeutics (RNA)?
Short answer · as of
Against analyst estimates the company has EPS beat 0 of the last 3 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2025 | $12M | -$37,000 | -$0.0022 (diluted) |
| Q4 FY2025 | $859,000 | -$48M | — |
| Q1 FY2026 | $20M | -$17M | -$0.97 (diluted) |
| Q2 FY2026 | $3M | -$20M | -$1.18 (diluted) |
What are the financial strengths and risks for Atrium Therapeutics (RNA)?
Short answer
The MoonshotScore pillars rate balance-sheet strength as strengths. What is holding it back is weak fundamentals, weak price trend. Trailing ratios: ROE -95.0% · ROA -34.8% · current ratio 10.46.
What should you watch next at Atrium Therapeutics (RNA)?
Short answer · as of
Current published price targets run low $15.00 · high $25.00 · consensus $20.00 · median $20.00 against a quoted price of $6.64 (as of Nov 18, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- No Altman Z or Piotroski screen is held for this filer.
Checked against the records this page reads, on the dates shown above.
How does Atrium Therapeutics compare with its peers?
Short answer
Atrium Therapeutics's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.33 Nov 18, 2026 | $471M | 91 5-pillar Nov 18, 2026 | |
| $9.28 Nov 18, 2026 | $552M | 91 5-pillar Nov 18, 2026 | |
| $3.02 Nov 18, 2026 | $255M | 90 5-pillar Nov 18, 2026 | |
| $42.53 Nov 18, 2026 | $801M | 88 5-pillar Nov 18, 2026 | |
| $11.25 Nov 18, 2026 | $102M | 82 5-pillar Nov 18, 2026 | |
| $15.26 Nov 18, 2026 | $85.5M | 82 5-pillar Nov 18, 2026 | |
| $3.89 Nov 18, 2026 | $169M | 72 5-pillar Nov 18, 2026 | |
| $1.96 Nov 18, 2026 | $186M | 69 5-pillar Nov 18, 2026 | |
| $12.48 Nov 18, 2026 | $884M | 69 5-pillar Nov 18, 2026 | |
| $9.30 Nov 18, 2026 | $546M | 68 5-pillar Nov 18, 2026 | |
| $29.68 Nov 18, 2026 | $993M | 64 5-pillar Nov 18, 2026 | |
| $8.32 Nov 18, 2026 | $813M | 63 5-pillar Nov 18, 2026 | |
| Atrium Therapeutics (RNA) — this page | $6.64 | $143M | 35 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $15.00 – $25.00
- Consensus target
- $20.00
- Median target
- $20.00
Consensus record · Captured .
Measured against a quoted price of $6.64 (as of Nov 18, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held RNA in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported RNA in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Atrium Therapeutics Stock: Key Questions Answered
These answers are editorial: they are written from question templates that restate figures shown above. They are not part of the source register.
What does the MoonshotScore mean for RNA?
RNA carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Atrium Therapeutics, Inc. is a biopharmaceutical company focused on developing RNA therapeutics for cardiomyopathies.
Is RNA a good stock to buy?
Stock Expert AI does not rate RNA buy, sell or hold. Atrium Therapeutics, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the RNA stock price today?
The last price recorded for Atrium Therapeutics, Inc. (RNA), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the RNA price target?
The analyst consensus price target for Atrium Therapeutics, Inc. (RNA), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the key factors to evaluate for RNA?
Atrium Therapeutics, Inc. (RNA) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. These partnerships could provide access to additional funding, expertise, and resources. Not financial advice.
How frequently does RNA data refresh on this page?
RNA's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven RNA's recent stock price performance?
Atrium Therapeutics, Inc. (RNA) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on innovative RNA therapeutics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider RNA overvalued or undervalued right now?
Atrium Therapeutics, Inc. (RNA) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of RNA?
Fractional-share availability for Atrium Therapeutics, Inc. (RNA) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 15 figures on this page — 9 from Financial Modeling Prep (FMP), 5 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com